LETTER _ O
FROM _ O
THE _ O
CHAIRMAN _ O
AND _ O
CO-CHAIRMAN _ O
K _ O
SATISH _ O
REDDY _ O
Chairman _ O
G _ O
V _ O
PRASAD _ O
Co-Chairman _ O
and _ O
Managing _ O
Director _ O
Ÿ _ O
In _ O
September _ O
2020 _ O
, _ O
when _ O
the _ O
� _ O
rst _ O
phase _ O
of _ O
the _ O
pandemic _ O
was _ O
still _ O
raging _ O
in _ O
India _ O
, _ O
Dr _ O
. _ O

Reddy _ O
’ _ O
s _ O
signed _ O
up _ O
with _ O
the _ O
Russian _ B-key
Direct _ I-key
Investment _ I-key
Fund _ I-key
( _ O
RDIF _ B-key
) _ O
— _ O
Russia _ O
’ _ O
s _ O
sovereign _ O
wealth _ O
fund _ O
— _ O
to _ O
cooperate _ O
on _ O
clinical _ O
trials _ O
and _ O
distribution _ O
of _ O
Sputnik _ O
V _ O
vaccine _ O
in _ O
India _ O
. _ O

Upon _ O
regulatory _ O
approval _ O
in _ O
India _ O
, _ O
RDIF _ B-key
committed _ O
to _ O
supply _ O
100 _ O
million _ O
doses _ O
of _ O
the _ O
vaccine _ O
to _ O
Dr _ O
. _ O

Reddy _ O
’ _ O
s _ O
. _ O

Ÿ _ O
Dedicated _ O
separate _ O
COVID _ B-key
- _ I-key
19 _ I-key
care _ O
facilities _ O
were _ O
launched _ O
for _ O
employees _ O
and _ O
dependents _ O
in _ O
three _ O
locations _ O
to _ O
provide _ O
pre-hospitalization _ O
care _ O
. _ O

Ÿ _ O
Thereafter _ O
, _ O
we _ O
created _ O
a _ O
partnership _ B-key
with _ O
the _ O
Biotechnology _ O
Industry _ O
Research _ O
Assistance _ O
Council _ O
( _ O
BIRAC _ O
) _ O
of _ O
the _ O
Department _ O
of _ O
Biotechnology _ O
, _ O
Government _ O
of _ O
India _ O
, _ O
for _ O
advisory _ O
support _ O
and _ O
to _ O
use _ O
some _ O
of _ O
BIRAC _ O
’ _ O
s _ O
clinical _ O
trial _ O
centers _ O
for _ O
clinical _ O
trials _ O
of _ O
Sputnik _ O
V _ O
vaccine _ O
. _ O

Your _ O
company _ O
’ _ O
s _ O
core _ O
dictum _ O
is _ O
‘ _ O
Good _ O
Health _ O
Can _ O
’ _ O
t _ O
Wait _ O
’ _ O
. _ O

Ÿ _ O
For _ O
employees _ O
working _ O
on-site _ O
, _ O
stringent _ O
social _ O
distancing _ O
and _ O
safety _ O
measures _ O
were _ O
deployed _ O
in _ O
work _ O
locations _ O
, _ O
transport _ O
facilities _ O
and _ O
cafeterias _ O
. _ O

Other _ O
measures _ O
included _ O
multiple _ O
stages _ O
of _ O
disinfection _ O
, _ O
provision _ O
of _ O
personal _ O
protective _ O
equipment _ O
, _ O
automating _ O
actions _ O
that _ O
require _ O
manual _ O
contact _ O
. _ O

Moreover _ O
, _ O
we _ O
provided _ O
a _ O
daily _ O
hardship _ O
allowance _ O
. _ O

Never _ O
before _ O
in _ O
the _ O
history _ O
of _ O
Dr _ O
. _ O

Reddy _ O
’ _ O
s _ O
has _ O
this _ O
maxim _ O
been _ O
more _ O
important _ O
than _ O
now _ O
. _ O

In _ O
the _ O
context _ O
of _ O
this _ O
horri _ O
� _ O
c _ O
pandemic _ B-key
, _ O
let _ O
us _ O
brie _ O
� _ O
y _ O
share _ O
with _ O
you _ O
what _ O
your _ O
company _ O
has _ O
done _ O
to _ O
address _ O
the _ O
situation _ O
. _ O

Ÿ _ O
A _ O
well-being _ O
and _ O
support _ O
plan _ O
that _ O
comprised _ O
tele-consulting _ O
, _ O
helplines _ O
, _ O
24x7 _ O
access _ O
to _ O
clinical _ O
psychologists _ O
through _ O
an _ O
online _ B-key
platform _ I-key
and _ O
a _ O
home _ O
isolation _ O
program _ O
. _ O

Ÿ _ O
We _ O
contracted _ O
for _ O
additional _ O
insurance _ O
coverage _ O
for _ O
COVID _ B-key
- _ I-key
19 _ I-key
which _ O
covered _ O
hospitalization _ O
and _ O
home _ O
quarantine _ O
expenses _ O
. _ O

This _ O
was _ O
extended _ O
to _ O
our _ O
employees _ O
and _ O
their _ O
dependents _ O
in _ O
India _ O
. _ O

Employees _ O
were _ O
also _ O
provided _ O
additional _ O
COVID _ O
- _ O
19 _ O
leave _ O
. _ O

At _ O
the _ O
same _ O
time _ O
, _ O
Dr _ O
. _ O

Reddy _ O
’ _ O
s _ O
acted _ O
quickly _ O
to _ O
bring _ O
various _ O
preventive _ O
and _ O
curative _ O
medicines _ O
to _ O
deal _ O
with _ O
COVID _ O
- _ O
19 _ O
, _ O
including _ O
a _ O
vaccine _ O
. _ O

Let _ O
us _ O
start _ O
with _ O
our _ O
vaccine _ O
journey _ O
. _ O

There _ O
has _ O
never _ O
been _ O
a _ O
year _ O
such _ O
as _ O
this _ O
. _ O

We _ O
pray _ O
that _ O
there _ O
never _ O
will _ O
be _ O
any _ O
more _ O
in _ O
our _ O
lifetime _ O
as _ O
well _ O
as _ O
of _ O
our _ O
children _ O
and _ O
grandchildren _ O
. _ O

Sputnik _ O
V _ O
vaccine _ O
As _ O
on _ O
May _ O
14 _ O
, _ O
2021 _ O
, _ O
the _ O
virus _ O
has _ O
infected _ O
over _ O
160 _ O
million _ O
and _ O
has _ O
claimed _ O
the _ O
lives _ O
of _ O
3.4 _ O
million _ O
people _ O
worldwide _ O
. _ O

India _ O
, _ O
the _ O
second _ O
worst _ O
infected _ O
country _ O
in _ O
the _ O
world _ O
, _ O
has _ O
witnessed _ O
over _ O
25 _ O
million _ O
cases _ O
and _ O
more _ O
than _ O
270,000 _ O
deaths _ O
. _ O

With _ O
the _ O
pandemic _ B-key
� _ O
aring _ O
for _ O
the _ O
� _ O
rst _ O
time _ O
in _ O
April _ O
2020 _ O
, _ O
the _ O
primary _ O
objective _ O
was _ O
to _ O
ensure _ O
health _ O
and _ O
safety _ O
of _ O
our _ O
employees _ O
and _ O
their _ O
families _ O
while _ O
continuing _ O
to _ O
supply _ O
medicines _ O
across _ O
the _ O
world _ O
. _ O

Some _ O
of _ O
the _ O
interventions _ O
that _ O
we _ O
quickly _ O
put _ O
in _ O
place _ O
were _ O
: _ O
Ÿ _ O
From _ O
December _ O
2020 _ O
, _ O
we _ O
commenced _ O
clinical _ O
trials _ O
of _ O
Sputnik _ O
V _ O
. _ O

Based _ O
on _ O
satisfactory _ O
data _ O
from _ O
Phase _ O
II _ O
trials _ O
, _ O
we _ O
received _ O
approval _ O
from _ O
the _ O
Drugs _ O
Controller _ O
General _ O
of _ O
India _ O
( _ O
DCGI _ O
) _ O
to _ O
conduct _ O
Phase _ O
III _ O
clinical _ O
trial _ O
on _ O
1,500 _ O
subjects _ O
as _ O
part _ O
of _ O
a _ O
randomized _ O
, _ O
double _ O
- _ O
blind _ O
, _ O
parallel-group _ O
, _ O
placebo-controlled _ O
study _ O
in _ O
India _ O
. _ O

Dr _ O
. _ O

Reddy _ O
’ _ O
s _ O
Laboratories _ O
Limited _ O
04 _ O
Dear _ O
Member _ O
, _ O
05 _ O
Annual _ B-key
Report _ I-key
2020 _ O
- _ O
21 _ O
G _ O
V _ O
Prasad _ O
Co-Chairman _ O
and _ O
Managing _ O
Director _ O
K _ O
Satish _ O
Reddy _ O
Chairman _ O
Ÿ _ O
Sputnik _ O
V _ O
makes _ O
Dr _ O
. _ O

Reddy _ O
’ _ O
s _ O
, _ O
the _ O
third _ O
enterprise _ O
in _ O
India _ O
that _ O
has _ O
been _ O
authorized _ O
to _ O
supply _ O
COVID _ O
- _ O
19 _ O
vaccines _ O
. _ O

c _ O
) _ O
2 _ O
- _ O
deoxy-D-glucose _ O
( _ O
2DG _ O
™ _ O
) _ O
: _ O
The _ O
2 _ O
- _ O
DG _ O
has _ O
been _ O
developed _ O
by _ O
Defence _ O
Research _ O
and _ O
Development _ O
Organization _ O
( _ O
DRDO _ O
) _ O
laboratories _ O
, _ O
in _ O
collaboration _ O
with _ O
Dr _ O
. _ O

Reddy _ O
’ _ O
s _ O
. _ O

The _ O
drug _ O
received _ O
emergency _ O
use _ O
approval _ O
as _ O
adjunct _ O
therapy _ O
for _ O
hospitalized _ O
moderate _ O
to _ O
severe _ O
COVID _ B-key
- _ I-key
19 _ I-key
patients _ O
. _ O

Ÿ _ O
Consolidated _ B-key
revenues _ I-key
were _ O
` _ O
189.7 _ O
billion _ O
, _ O
or _ O
a _ O
9% _ O
growth _ O
over _ O
the _ O
previous _ O
year _ O
. _ O

To _ O
retain _ O
basic _ O
continuity _ O
across _ O
our _ O
annual _ O
letters _ O
, _ O
let _ O
us _ O
share _ O
the _ O
consolidated _ O
� _ O
nancial _ O
results _ O
of _ O
your _ O
company _ O
for _ O
FY2021 _ O
. _ O

Ÿ _ O
In _ O
February _ O
2021 _ O
, _ O
we _ O
initiated _ O
the _ O
process _ O
with _ O
DCGI _ O
for _ O
Emergency _ O
Use _ O
Authorization _ O
of _ O
Sputnik _ O
V _ O
. _ O

This _ O
authorization _ O
was _ O
granted _ O
in _ O
April _ O
2021 _ O
. _ O

Ÿ _ O
On _ O
May _ O
1 _ O
, _ O
2021 _ O
, _ O
the _ O
� _ O
rst _ O
consignment _ O
of _ O
imported _ O
doses _ O
of _ O
the _ O
Sputnik _ O
V _ O
vaccine _ O
landed _ O
in _ O
India _ O
. _ O

These _ O
received _ O
regulatory _ O
clearance _ O
from _ O
the _ O
Central _ O
Drugs _ O
Laboratory _ O
, _ O
Kasauli _ O
, _ O
on _ O
May _ O
13 _ O
, _ O
2021 _ O
. _ O

The _ O
soft _ O
launch _ O
of _ O
the _ O
vaccine _ O
commenced _ O
and _ O
the _ O
� _ O
rst _ O
dose _ O
of _ O
the _ O
vaccine _ O
was _ O
administered _ O
in _ O
Hyderabad _ O
on _ O
May _ O
14 _ O
, _ O
2021 _ O
. _ O

Ÿ _ O
Further _ O
consignments _ O
of _ O
imported _ B-key
doses _ O
are _ O
expected _ O
over _ O
the _ O
coming _ O
period _ O
. _ O

Subsequently _ O
, _ O
supply _ O
of _ O
the _ O
Sputnik _ O
V _ O
vaccine _ O
will _ O
commence _ O
from _ O
Indian _ O
manufacturing _ O
partners _ O
. _ O

Your _ O
company _ O
is _ O
working _ O
closely _ O
with _ O
six _ O
manufacturing _ O
partners _ O
in _ O
India _ O
to _ O
ful _ O
� _ O
l _ O
regulatory _ O
requirements _ O
to _ O
ensure _ O
smooth _ O
and _ O
timely _ O
supply _ O
. _ O

Ÿ _ O
Simultaneously _ O
, _ O
Sputnik _ O
V _ O
showed _ O
strong _ O
e _ O
� _ O
cacy _ O
, _ O
immunogenicity _ O
and _ O
safety _ O
results _ O
in _ O
Phase _ O
III _ O
clinical _ O
trials _ O
conducted _ O
on _ O
19,866 _ O
people _ O
in _ O
Russia _ O
by _ O
RDIF _ O
. _ O

The _ O
e _ O
� _ O
cacy _ O
of _ O
Sputnik _ O
V _ O
against _ O
COVID _ B-key
- _ I-key
19 _ I-key
was _ O
reported _ O
at _ O
91.6% _ O
. _ O

Ÿ _ O
We _ O
will _ O
work _ O
closely _ O
with _ O
stakeholders _ B-key
in _ O
the _ O
government _ O
and _ O
the _ O
private _ O
sector _ O
in _ O
India _ O
to _ O
ensure _ O
the _ O
widest _ O
possible _ O
reach _ O
of _ O
the _ O
Sputnik _ O
V _ O
vaccine _ O
as _ O
part _ O
of _ O
the _ O
national _ O
inoculation _ O
e _ O
� _ O
ort _ O
. _ O

This _ O
is _ O
a _ O
rea _ O
� _ O
rmation _ O
of _ O
our _ O
determination _ O
to _ O
� _ O
ght _ O
against _ O
the _ O
COVID _ O
- _ O
19 _ O
pandemic _ O
in _ O
India _ O
. _ O

a _ O
) _ O
Remdesivir _ O
: _ O
We _ O
signed _ O
a _ O
licensing _ O
agreement _ O
with _ O
Gilead _ O
Sciences _ O
, _ O
Inc _ O
. _ O

that _ O
grants _ O
us _ O
the _ O
right _ O
to _ O
register _ O
, _ O
manufacture _ O
and _ O
sell _ O
Remdesivir _ O
, _ O
a _ O
potential _ O
treatment _ O
for _ O
COVID _ O
- _ O
19 _ O
, _ O
in _ O
127 _ O
countries _ O
including _ O
India _ O
. _ O

We _ O
launched _ O
Remdesivir _ O
under _ O
the _ O
brand _ O
name _ O
“ _ O
Redyx _ O
™ _ O
” _ O
in _ O
India _ O
in _ O
September _ O
2020 _ O
. _ O

With _ O
the _ O
surge _ O
of _ O
COVID _ O
- _ O
19 _ O
cases _ O
in _ O
the _ O
second _ O
wave _ O
, _ O
we _ O
ramped-up _ O
our _ O
capacities _ O
to _ O
increase _ O
availability _ O
of _ O
the _ O
medicine _ O
. _ O

® _ O
b _ O
) _ O
Avigan _ O
( _ O
Favipiravir _ O
) _ O
: _ O
We _ O
entered _ O
into _ O
a _ O
licensing _ O
agreement _ O
with _ O
Fuji _ O
� _ O
lm _ O
Toyama _ O
Chemical _ O
Co _ O
. _ O

Ltd _ O
. _ O
to _ O
develop _ O
, _ O
sell _ O
and _ O
® _ O
distribute _ O
Avigan _ O
( _ O
Favipiravir _ O
) _ O
in _ O
all _ O
countries _ O
other _ O
than _ O
Japan _ O
, _ O
China _ O
and _ O
Russia _ O
. _ O

This _ O
has _ O
enabled _ O
us _ O
to _ O
launch _ O
® _ O
Avigan _ O
200 _ O
mg _ O
tablets _ O
in _ O
India _ O
and _ O
few _ O
other _ O
markets _ O
. _ O

We _ O
are _ O
also _ O
conducting _ O
Phase _ O
III _ O
trials _ O
in _ O
North _ O
America _ O
for _ O
outpatient _ O
setting _ O
with _ O
mild _ O
to _ O
moderate _ O
symptoms _ O
. _ O

Sputnik _ O
V _ O
is _ O
not _ O
the _ O
only _ O
commitment _ O
of _ O
your _ O
company _ O
regarding _ O
COVID _ O
- _ O
19 _ O
treatments _ O
. _ O

In _ O
addition _ O
, _ O
we _ O
have _ O
been _ O
involved _ O
in _ O
three _ O
other _ O
medicines _ O
. _ O

We _ O
are _ O
also _ O
working _ O
on _ O
Molnupiravir _ O
, _ O
Baricitinib _ O
and _ O
other _ O
COVID _ O
- _ O
19 _ O
drugs _ O
for _ O
treatment _ O
ranging _ O
from _ O
mild _ O
to _ O
severe _ O
conditions _ O
. _ O

Ÿ _ O
Consolidated _ O
gross _ O
pro _ O
� _ O
t _ O
was _ O
` _ O
103.1 _ O
billion _ O
, _ O
which _ O
was _ O
10% _ O
greater _ O
vis-à-vis _ O
FY2020 _ O
. _ O

Ÿ _ O
Earnings _ O
before _ O
interest _ B-key
, _ O
taxes _ B-key
, _ O
depreciation _ B-key
and _ O
amortization _ B-key
( _ O
EBITDA _ B-key
) _ O
increased _ O
to _ O
` _ O
47.4 _ O
billion _ O
, _ O
or _ O
an _ O
increase _ O
of _ O
2% _ O
versus _ O
the _ O
previous _ O
year _ O
. _ O

Ÿ _ O
Pro _ O
� _ O
t _ O
before _ O
taxes _ O
( _ O
PBT _ B-key
) _ O
was _ O
` _ O
26.4 _ O
billion _ O
, _ O
which _ O
was _ O
46% _ O
higher _ O
than _ O
` _ O
18 _ O
billion _ O
earned _ O
in _ O
the _ O
previous _ O
year _ O
. _ O

Ÿ _ O
Pro _ O
� _ O
t _ O
after _ O
taxes _ O
( _ O
PAT _ B-key
) _ O
was _ O
` _ O
17.2 _ O
billion _ O
, _ O
or _ O
12% _ O
less _ O
than _ O
in _ O
FY2020 _ O
. _ O

Ÿ _ O
Diluted _ O
earnings _ B-key
per _ I-key
share _ I-key
( _ O
EPS _ B-key
) _ O
was _ O
` _ O
103.65 _ O
in _ O
FY2021 _ O
, _ O
versus _ O
` _ O
117.40 _ O
in _ O
FY2020 _ O
. _ O

Two _ O
of _ O
our _ O
key _ O
promises _ O
have _ O
been _ O
addressing _ O
unmet _ O
patient _ O
needs _ O
, _ O
and _ O
helping _ O
patients _ O
to _ O
manage _ O
disease _ O
better _ O
. _ O

Nothing _ O
has _ O
underscored _ O
the _ O
importance _ O
of _ O
these _ O
promises _ O
as _ O
the _ O
COVID _ B-key
- _ I-key
19 _ I-key
pandemic _ B-key
. _ O

We _ O
do _ O
not _ O
know _ O
when _ O
the _ O
second _ O
wave _ O
will _ O
subside _ O
. _ O

Neither _ O
do _ O
we _ O
know _ O
whether _ O
there _ O
will _ O
be _ O
a _ O
third _ O
wave _ O
and _ O
of _ O
what _ O
intensity _ O
. _ O

But _ O
we _ O
do _ O
know _ O
that _ O
the _ O
only _ O
preventive _ O
worth _ O
the _ O
name _ O
is _ O
vaccination _ O
. _ O

And _ O
we _ O
are _ O
committed _ O
to _ O
seeing _ O
that _ O
your _ O
company _ O
plays _ O
a _ O
key _ O
role _ O
in _ O
the _ O
vaccinating _ O
program _ O
for _ O
our _ O
citizens _ O
. _ O

Because _ O
Good _ O
Health _ O
Can _ O
’ _ O
t _ O
Wait _ O
. _ O

Many _ O
of _ O
us _ O
have _ O
lost _ O
loved _ O
ones _ O
during _ O
this _ O
pandemic _ O
, _ O
especially _ O
in _ O
the _ O
second _ O
wave _ O
. _ O

Our _ O
sincerest _ O
condolences _ O
to _ O
them _ O
and _ O
our _ O
prayers _ O
that _ O
the _ O
families _ O
have _ O
the _ O
spirit _ O
and _ O
strength _ O
to _ O
overcome _ O
their _ O
tragedies _ O
. _ O

With _ O
our _ O
best _ O
regards _ O
and _ O
prayers _ O
, _ O
Ÿ _ O
Operating _ O
pro _ O
� _ O
t _ O
increased _ O
by _ O
52% _ O
to _ O
` _ O
24.3 _ O
billion _ O
. _ O

We _ O
wish _ O
to _ O
take _ O
this _ O
opportunity _ O
of _ O
thanking _ O
every _ O
employee _ O
of _ O
your _ O
company _ O
for _ O
putting _ O
in _ O
all _ O
the _ O
extra _ O
e _ O
� _ O
orts _ O
in _ O
these _ O
trying _ O
times _ O
to _ O
make _ O
these _ O
results _ O
happen _ O
. _ O

They _ O
have _ O
done _ O
spectacular _ O
work _ O
. _ O

Stay _ O
safe _ O
. _ O

Vaccinate _ O
as _ O
soon _ O
as _ O
you _ O
can _ O
. _ O

Wear _ O
masks _ O
. _ O

Maintain _ O
social _ O
distancing _ O
. _ O

This _ O
, _ O
too _ O
, _ O
shall _ O
pass _ O
. _ O

But _ O
it _ O
needs _ O
our _ O
combined _ O
e _ O
� _ O
orts _ O
. _ O

And _ O
determination _ O
to _ O
succeed _ O
. _ O

